Human Dachshund homologue 1 (DACH1) is a major component of the Retinal Determination Gene Network. Loss of DACH1 expression was found in breast, prostate, lung, endometrial, colorectal and hepatocellular carcinoma. To explore the expression, regulation and function of DACH1 in human esophageal cancer, 11 esophageal cancer cell lines, 10 cases of normal esophageal mucosa, 51 cases of different grades of dysplasia and 104 cases of primary esophageal squamous cancer were employed. Methylation specific PCR, immunohistochemistry, western blot, flow cytometry, small interfering RNAs, colony formation techniques and xenograft mice model were used. We found that DACH1 expression was regulated by promoter region hypermethylation in esophageal cancer cell lines. 18.8% (6 of 32) of grade 1, 42.1% (8 of 19) of grade 2 and grade 3 dysplasia (ED2,3), and 61.5% (64 of 104) of esophageal cancer were methylated, but no methylation was found in 10 cases of normal esophageal mucosa. The methylation was increased in progression tendency during esophageal carcinogenesis (P<0.01). DACH1 methylation was associated with poor differentiation (P<0.05) and late tumor stage (P<0.05). Restoration of DACH1 expression inhibited cell growth and activated TGF-β signaling in KYSE150 and KYSE510 cells. DACH1 suppressed human esophageal cancer cell tumor growth in xenograft mice. In conclusion, DACH1 is frequently methylated in human esophageal cancer and methylation of DACH1 is involved in the early stage of esophageal carcinogenesis. DACH1 expression is regulated by promoter region hypermethylation. DACH1 suppresses esophageal cancer growth by activating TGF-β signaling.
Citation: Wu L, Herman JG, Brock MV, Wu K, Mao G, Yan W, et al. (2014) Silencing DACH1 Promotes Esophageal Cancer Growth by Inhibiting TGF-β Signaling. PLoS ONE 9(4): e95509. doi:10.1371/journal.pone.0095509
Editor: Dajun Deng, Peking University Cancer Hospital and Institute, China
Received: February 17, 2014; Accepted: March 26, 2014; Published: April 17, 2014
Copyright: © 2014 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from:the National Basic Research Program (973 Program No. 2012CB934002, 2010CB912802), National High-tech R&D Program (863 Program No. SS2012AA020314, SS2012AA020821, SS2012AA020303), National Key Scientific Instrument Special Programme of China (Grant No. 2011YQ03013405) and National Science Foundation of China (Grant No. 81121004, 81071953, 81161120432, 81072169, 81172422, 81261120395). The URLs of funder's websites are: National Basic Research Program: http://www.973.gov.cn/Default_3.aspx; National High-tech R&D Program: http://www.863.gov.cn/; National Key Scientific Instrument Special Programme of China: http://www.most.gov.cn/index.htm; National Science Foundation of China: http://www.nsfc.gov.cn/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: JGH is a consultant to MDxHealth, however, this does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Esophageal cancer is the fifth most malignant disease and has been ranked as the fourth leading cause of cancer related deaths in China.  Esophageal squamous cell carcinoma (ESCC) is the predominant histological type of esophageal cancer, and accounts for approximately 90% of esophageal cancer cases in the northern and central China.  Despite the development of multimodal therapies, the 5 year overall survival remains below 20%.  The mechanisms of esophageal carcinogenesis remain unclear. Multiple genetic and epigenetic alterations were regarded as important factors for developing esophageal cancer –.
Dachshund homolog 1 (DACH1), a major component of the Retinal Determination Gene Network, is widely expressed in epithelial cells. Reduction of DACH1 expression was associated with poor prognosis in breast, prostate, lung, endometrial, colorectal and hepatic cancer. – The expression of DACH1 was regulated by promoter region hypermethylation in endometrial, colorectal and hepatocellular cancer. – DACH1 suppressed human hepatocellular carcinoma by activating TGF-β signaling.  While the epigenetic changes and the function of DACH1 in human ESCC remain unclear. In this study, we mainly analyzed the epigenetic changes and the mechanism of DACH1 on esophageal carcinogenesis.
Materials and Methods
The study protocols were approved by the Ethics Committee of the Chinese PLA General Hospital (Permit Number: 20090701-015), and written informed consent was obtained from the participants. All procedures of animal research were approved by the Animal Ethics Committee of the Chinese PLA General Hospital (Permit Number: 2013-X8-40) and all efforts were made to minimize suffering. The study was carried out in accordance with the guidelines of the 1975 Declaration of Helsinki and was consistent with good clinical practice guidelines and local regulatory requirements.
Primary Human Tissue Samples and Cell Lines
A total of 104 cases of primary esophageal squamous cell carcinoma were collected as fresh frozen tissue from Chinese PLA General Hospital. All samples were classified by TNM stage, including stage I (N = 5), stage II (N = 66), stage III (N = 32), and stage IV (N = 1). Fifty one cases of esophageal dysplasia were collected as paraffin-embedded samples, including 32 cases of grade 1 dysplasia (ED1), 11 cases of grade 2 dysplasia (ED2) and 8 cases of grade 3 dysplasia (ED3). Ten cases of normal esophageal mucosa (NE) were collected by biopsy under endoscopy from Chinese PLA General Hospital. Among 104 cancer samples, 30 cases of paraffin blocks were available with matched adjacent tissue. Eleven human ESCC cell lines (KYSE30, KYSE70, KYSE140, KYSE150, KYSE180, KYSE410, KYSE450, KYSE510, TE1, TE3 and TE8) were included in this study. All ESCC cell lines were described previously –, and maintained in RPMI-1640 (Invitrogen) supplemented with 10% fetal bovine serum and antibiotics. The Ethics Committee of the Chinese PLA General Hospital approved this study (Permit Number: 20090701-015), and written informed consent was obtained before the collection of tissue sample and cell lines.
5-Aza-2′-deoxycytidine Treatment, RNA Isolation and Semi-quantitative Reverse Transcription-PCR
ESCC cell lines were split to low density (30% confluence) 12 hours before treatment. Cells were treated with 5-aza-2′-deoxycytidine (5-AZA) (Sigma-Aldrich) at a concentration of 2 µM in the growth medium, which was exchanged every 24 h for a total 96-h treatment. At the end of treatment course, cells were collected and total RNA was isolated by Trizol reagent (Invitrogen). Semi-quantitative reverse transcription-PCR (RT-PCR) was performed as described Previously .
Bisulfite Modification, Methylation Specific PCR and Bisulfite Sequencing
Genomic DNA from ESCC cell lines and primary ESCC tissues were prepared by proteinase-K method. Methylation Specific PCR (MSP) and Bisulfite Sequencing (BSSQ) were performed as described previously. ,  MSP primers and BSSQ primers  were designed according to genomic sequences around transcription start site in the CpG island of DACH1 gene (GenBank NM_080759.4) promoter region and synthesized (BGI) to detect unmethylated (U) and methylated (M) alleles.
Immunohistochemical staining for DACH1 was performed on 4µm thick serial sections derived from formal dehyde-fixed paraffin blocks using antibody against DACH1 (1∶500 dilution, Proteintech) as described previously.  The staining intensity and extent of the stained area were graded according to the German semi-quantitative scoring system, which was also described previously .
Plasmid Construction and Transfection
The DACH1 expression vector was a gift from Dr. Cvekl. The DACH1 expression vector and the Smad-binding elements (SBE)-4 Luc reporter plasmid were described previously.  DACH1 was also subcloned into plenti6-GFP vector. Shuttle vector constructs and the ViraPower Packaging Mix were cotransfected 293FT cells to obtain lentivirus according to the manufacturer’s protocol (Invitrogen). Lentivirus was then added to KYSE510 and KYSE150 cells, and sceened by Blasticidin (5 µg/ml, Invitrogen) to generate DACH1 stably expressed cells. Lipofectamine 2000 (Invitrogen) was used for plasmid transfection. All constructs were confirmed by sequencing.
Cell Viability Assay
DACH1 stably expressed cells and unexpressed control were seeded onto 96-well plates (3×103 cells/well), and the cell viability was measured daily for 96 hours using the Cell Counting Kit-8 (Dojindo Laboratorie) according to instructions of the manufacturer. The results were plotted as means ± SD. All assays were performed in triplicate and repeated for three times.
Colony Formation Assay
DACH1 stably expressed cells and unexpressed control (5×102 cells/well) were plated in 2 ml complete growth medium. The medium and reagents were changed once at 72 hours. After 2 weeks incubation, cells were fixed with 75% ethanol for 30 minutes and stained with 0.2% crystal violet (Beyotime) for 20 minutes and counting. For each experiment, the colony formation assay was performed three times.
Flow Cytometry Analysis
For cell cycle analysis, the Cell Cycle Detection Kit (KeyGen Biotech) was used according to manufacturer’s instructions. Each sample was analyzed by flow cytometry with a FACScan Flow Cytometer (Becton-Dickinson) using a 488 nm laser. Histograms were analyzed for cell cycle compartments using ModFit version 2.0 (Verity Software House). For apoptosis analysis, the Annexin V-FITC Apoptosis Detection Kit (KeyGen Biotech) was conducted according to manufacturer’s instructions.
DACH1 Knock down by siRNA
Four selected small interfering RNAs (siRNA) targeting DACH1 and RNAi Negative Control Duplex were used in this study, and the sequences were described previously.  RNAi oligonucleotide or RNAi Negative Control Duplex (GenePharma) was transfected into KYSE140 cells using Lipofectamine RNAiMAX Reagent (Invitrogen), according to manufacturer’s instructions.
Dual-luciferase Reporter Assay
KYSE510 and KYSE150 cells (3×103) were seeded onto 96-well plates, incubated for 24 hours and transfected with an appropriate combination of the reporter, expression plasmids and control vector, including SBE4-luc reporter plasmid (20 ng/well), pRL-TK control vector (2 ng/well) as an internal control reporter, and increasing amounts of DACH1 exprssion plasmid. Cells were serum-starved for 36 hours and then stimulated with or without TGF-β1 (Peprotech) for 12 hours before luciferase assay. Relative luciferase activities were measured with the Dual Luciferase Reporter Assay system (Promega) according to the manufacturer’s instructions. For each experiment, the luciferase reporter assay was performed three times.
Protein Preparation and Western Blot Analysis
Protein isolation and western blot were performed as described previously.  Primary antibodies were as following: DACH1 (Proteintech); c-Myc, p21, phospho-Smad3, cyclinD1 (Cell signaling Technology); CDK4 (Affinity); phospho-Smad2 (Millipore); cyclinE1, CDK2, Smad2 and Smad3 (Bioworld Technology); β-Actin (Beyotime). The blots were visualized using enhanced chemiluminescence (Pierce Bioscience).
In vivo Tumorigenicity
DACH1 stably expressed KYSE510 cells and unexpressed control (4×106 cells in 0.2 ml phosphate-buffered saline) was subcutaneously injected into the dorsal flank of 5-week-old female BABL/c nude mice respectively; each group included 5 mice. The tumor size was measured every 5 days for 4 weeks since 5 days after implantation, and the tumor volume was determined with the following formula: tumor volume (mm3) = [length (mm)]×[width (mm)]2/2. All procedures were approved by the Animal Ethics Committee of the Chinese PLA General Hospital (Permit Number: 2013-X8-40). All efforts were made to minimize suffering.
Data collected from multiple independent experiments were presented as the mean ± SEM, and analyzed using the Student’s t test. DACH1 expression level between esophageal cancer and matched adjacent tissue samples were compared using the Wilcoxon signed-rank test. Spearman’s rank correlation coefficient was calculated for the evaluation of the correlation between expression and methylation of DACH1. The relationship between clinicopathologic characteristics and DACH1 methylation status were analyzed using chi-square test. A p value of less than 0.05 was considered statistical significance. All statistical analyses were performed using SPSS 15.0 software.
DACH1 Expression is down Regulated by Promoter Region Hypermethylation in ESCC Cell Lines
DACH1 expression was regulated by promoter region hypermethylation in human colorectal and hepatocellular carcinoma. ,  To explore the regulation of DACH1 in ESCC, the expression and the methylation status of DACH1 were detected by RT-PCR and MSP in esophageal cancer cell lines. As shown in figure 1A, Loss of DACH1 expression was found in KYSE150, KYSE510, TE1 and TE3 cells, reduced DACH1 expression was appeared in TE8 cells, and expression of DACH1 was detected in KYSE30, KYSE70, KYSE140, KYSE180, KYSE450 and KYSE410 cells. MSP results were shown in figure 1B. DACH1 was completely methylated in KYSE150, KYSE510, TE1 and TE3 cells, partially in TE8, and unmethylated in KYSE30, KYSE70, KYSE140, KYSE180, KYSE450 and KYSE410 cells. MSP results were further validated by bisulfite sequencing (BSSQ) in KYSE150, KYSE510, TE8 and KYSE140 cells (Fig. 1C). Above results indicate that promoter region hypermethylation is correlated with loss/reduction of DACH1 expression. Re-expression/increasing expression of DACH1 was induced by 5-aza-2′-deoxycytidine (5-AZA) in DACH1 methylated esophageal cancer cell lines (KYSE150, KYSE510,TE8, Fig. 1A). These data suggest that DACH1 expression is regulated by promoter region methylation in ESCC cell lines.
(A) DACH1 expression level detected by RT-PCR in esophageal cancer cell lines. (B) Methylation status in promoter region; IVD: in vitro methylated DNA, used as methylation control; NL: normal blood lymphocyte DNA, used as unmethylation control; U: unmethylated alleles; M: methylated alleles. (C) BSSQ of DACH1 promoter region (−426 bp to −140 bp) in KYSE150, KYSE510, TE8 and KYSE140 cells; double-headed arrow: MSP PCR product, spanning 130 bp. Filled circles: methylated CpG sites; open circles: unmethylated CpG sites.
DACH1 is Frequently Methylated in Human Esophageal Cancer
To further explore the methylation status of DACH1 during human ESCC development, 10 cases of normal esophageal mucosa, 51 cases of different grades of dysplasia and 104 cases of primary ESCC were detected by MSP. As shown in figure 2A and 2B, 18.8% (6 of 32) of esophageal grade 1 dysplasia (ED1), 42.1% (8 of 19) of grade 2 and grade 3 dysplasia (ED2,3), and 61.5% (64 of 104) of invasive esophageal cancer (EC) were methylated, but none of the 10 cases of normal esophageal mucosa was methylated. The frequency of DACH1 methylation was increased in progression tendency during esophageal carcinogenesis (P<0.01). DACH1 methylation was associated with poor differentiation (P<0.05) and late tumor stage (P<0.05) significantly. No association was found between DACH1 methylation and age, gender, metastasis or tumor size (P>0.05, Table 1). Above results indicate that DACH1 methylation is an early event of esophageal carcinogenesis and methylation of DACH1 is accumulated during progression of esophageal cancer. The expression of DACH1 was evaluated by immunohistochemistry (IHC) in 30 cases of matched esophageal cancer and adjacent tissue samples. The expression was reduced significantly in cancer samples (P<0.01, Fig. 2C and 2D). It suggest that DACH1 is a possible tumor suppressor in esophageal cancer. To see if DACH1 expression was regulated by DNA methylation in human primary cancer, the association of DACH1 expression and promoter region hypermethylation was analyzed. Reduced expression was found in 19 cases of cancer tissue and 15 cases were methylated (Fig. 2E). Reduction of DACH1 expression was associated with promoter region hypermethylation significantly (P<0.01). These results suggest that DACH1 expression is regulated by promoter region hypermethylation in human primary ESCC.
(A) Representative MSP results of DACH1 methylation status in normal esophageal mucosa (NE), esophageal dysplasia (ED) and esophageal cancer (EC). (B) DACH1 methylation frequency in NE, ED1, ED2 and ED3, and EC. The frequency of methylated DACH1 were plotted according to histological grade and analyzed using chi-square test. **, P<0.01. (C) Representative IHC results for DACH1 expression in primary esophageal cancer (left) and adjacent tissues (right); upper phase, X200; lower phase, X400. (D) DACH1 expression level in 30 cases matched primary cancer and adjacent tissue samples; box plot: represents DACH1 expression level; horizontal line: represent the median level; the top and bottom line of the boxes represent 75% and 25% expression level, respectively; vertical bars represent different expression level. **, P<0.01 versus adjacent tissue samples by using Wilcoxon signed-rank test. (E) The association of DACH1 methylation and loss/reduced expression in 30 cases ESCC. **, P<0.01, Spearman’s rank correlation coefficient.
Restoration of DACH1 Expression Suppresses Esophageal Cancer Growth both in vitro and in vivo
To see the effect of DACH1 on ESCC cell proliferation, KYSE510 and KYSE150 cells with stably expressing DACH1 or empty vector were established by lentivirus transduction. Cell viability and colony formation were analyzed in DACH1 stably expressed cells and unexpressed control. Re-expression of DACH1 inhibited cell proliferation (P<0.01, Fig. 3A) and colony formation (P<0.05, Fig. 3B) in these cell lines. The function of DACH1 on esophageal cancer was also studied in xenograft mice model (Fig. 3C). The tumor size was smaller in DACH1 expressed KYSE510 cells than in control (104.23±21.38 mm3 vs 494.65±81.98 mm3, P<0.01, Fig. 3D), and the tumor weight was less in DACH1 expressed KYSE510 cells than in control group (78±28 mg vs 182±37 mg, P<0.01, Fig. 3E). The expression of DACH1 was validated by IHC in xenograft (Fig. 3F). These results suggest that DACH1 suppresses esophageal cancer growth both in vitro and in vivo.
(A) Growth curves represent CCK-8 assay results for DACH1 expressed cells and unexpressed cells.Points, mean of four independent experiments; bars, SEM. **, P<0.01, Student’s t test. (B) Representative results of colony formation in DACH1 expressed and unexpressed KYSE510 and KYSE150 cell lines. Columns, mean of four independent experiments; bars, SEM. *, P<0.05 versus controls by using the Student’s t test. (C) Representatives results of xenograft tumors in nude mice for DACH1 expressed and unexpressed KYSE510 cells. (D) Growth curves represent tumor size in DACH1 expressed and unexpressed KYSE510 cells xenograft mice in different time. Points, mean of 5 mice; bars, SEM.*, P<0.01, Student’s t test. (E) Representative results of tumor weight in DACH1 expressed and unexpressed KYSE510 cells xenograft mice in different time. Columns, mean of 5 mice; bars, SEM. *, P<0.01, Student’s t test. (F) Representive DACH1 expression results detected by IHC for DACH1 expressed and unexpressed KYSE510 cells xenograft. DACH1 expression was found in DACH1 expressed KYSE510 cell xenograft. (right). Magnification: upper phase, X200; lower phase, X400.
Restoration of DACH1 Expression Increased G1 Phase and Reduced S Phase Cells
The effect of DACH1 on cell cycle was analyzed by flow cytometry in KYSE510 and KYSE150 cell lines. As shown in figure 4A, The ratio of G1 phase cell was 51.05±2.28% and 38.56±1.64% in DACH1 expressed and unexpressed KYSE510 cell lines (P<0.05). The ratio of S phase was 25.72±0.99% and 37.09±1.49% in DACH1 expressed and unexpressed KYSE510 cell lines (P<0.05). The ratio of G1 phase cell was 65.46±2.84% and 44.41±2.87% in DACH1 expressed and unexpressed KYSE150 cell lines (P<0.05). The ratio of S phase was 12.34±0.10% and 32.06±1.32% in DACH1 expressed and unexpressed KYSE150 cell lines (P<0.01). These results suggest that DACH1 increases G1 phase and reduced S phase cells in esophageal cancer.
(A) Flow cytometry results show: the cell phase distribution in DACH1 unexpressed and expressed KYSE510 and KYSE150 cells. Columns, mean of three independent experiments; bars, SEM. *, P<0.05; **, P<0.01, Student’s t test. (B) Western blot results show: expression of G1/S check point related genes in DACH1 unexpressed and expressed KYSE510 and KYSE150 cells, β-Actin was used as a loading control.
Increased expression of CDK2, CDK 4, cyclinD1 and cyclinE1 usually represents promoting cell cycle from the G1 phase to S phase. As shown in figure 4B, the expression of CDK2, CDK 4, cyclinD1 and cyclinE1 were reduced apparently in DACH1 expressed KYSE510 and KYSE150 cells compared with unexpressed cells. It suggests that DACH1 suppresses cell proliferation by inhibiting G1/S checkpoint in esophageal cancer. The effect of DACH1 on cell apoptosis was also analyzed by flow cytometry in KYSE510 and KYSE150 cell lines, but no apoptosis change was found before and after restoration of DACH1 expression in these two cell lines (data not shown).
Restoration of DACH1 Expression Activates TGF-β Signaling in ESCC
Our previous study found that DACH1 performed anti-proliferation effect by activating TGF-β signaling and inhibiting c-Myc expression in human hepatocellular carcinoma cell lines.  To determine whether the TGF-β signaling is regulated by DACH1 in ESCC, dual-luciferase reporter assay was employed to examine SBE4 luciferase activity in KYSE510 and KYSE150 cell lines. As shown in figure 5A, SBE4 promoter activity was increased more than 3 fold in KYSE510 and 2.6 fold in KYSE150 cells after restoration of DACH1 expression, and the activity was increased in a dose-dependent manner by restoration of DACH1 expression combined with TGF-β1 treatment. To further understand the mechanism of DACH1 on TGF-β signaling, the level of phosphorylated Smad2 (p-Smad2) and phosphorylated Smad3 (p-Smad3), and its downstream targets, p21 and c-Myc were evaluated in DACH1 unexpressed and expressed KYSE510 and KYSE150 cell lines. The level of p-Smad2 was not changed before and after re-expression of DACH1, while the level of p-Smad3 was increased after re-expression of DACH1. The level of p-Smad2 and p-Smad3 were increased after adding TGF-β1. p-Smad3 was increased apparently when added TGF-β1 to DACH1 re-expressed KYSE510 and KYSE150 cells. The expression of downstream genes were different. p21 was up-regulated and c-Myc was down-regulated after re-expression of DACH1 (Fig. 5B). It hints that TGF-β signaling is activated by DACH1 and TGF-β1 enhances this effect. To further validate the effect of DACH1 on TGF-β signaling, siRNA knockdown technique was employed. The level of p-Smad2 didn’t change after knocking down DACH1 in DACH1 expressed KYSE140 cells, but the level of p-Smad3 was reduced when knocking down DACH1. Both p-Smad2 and p-Smad3 were increased after adding TGF-β1. p-Smad3 was increased slightly by adding TGF-β1 to siRNA transfected KYSE140 cells compared with only knocking down DACH1. Reduced p21 and increased c-Myc expression were found after knocking down DACH1 in KYSE140 cells (Fig. 5C and 5D). Above results further suggest that TGF-β signaling is activated by DACH1 in human esophageal cancer.
(A) Smad-binding elements (SBE)-4 Luc reporter activities in KYSE510 and KYSE150 cells. Columns, mean of three independent experiments; bars, SEM. (B) The expression level of TGF-β signaling downstream genes in DACH1 expressed cells and unexpressed cells, β-Actin was used as a loading control. (C) The efficiency of siRNAs targeting on DACH1 in KYSE140 cells. (D) The expression level of TGF-β signaling downstream genes in DACH1-siRNA KYSE140 cells and control group, β-Actin was used as a loading control.
The expression of DACH1 was reduced in breast, prostate, lung, endometrial, colorectal and hepatocellular carcinoma, but it was increased in ovarian cancer. –,  DACH1 expression was regulated by promoter region hypermethylation in endometrial, colorectal and hepatocellular carcinoma. – In the present study, we demonstrated that DACH1 expression was reduced and the expression of DACH1 was regulated by promoter region hypermethylation in human esophageal cancer. We had reported that many tumor suppressors were methylated with a progression tendency during esophageal carcinogenesis. , , ,  In this study, we analyzed the methylation status of DACH1 in normal esophageal mucosa, different grades of dysplasia and invasive cancer. DACH1 was frequently methylated in esophageal cancer and the frequency was increased with the progression of esophageal carcinogenesis from normal esophageal mucosa to invasive cancer. It suggests that DACH1 is an esophageal cancer early detection marker. The association of poor differentiation and late tumor stage with DACH1 methylation suggests that DACH1 methylation may serve as esophageal cancer prognostic marker.
DACH1 was regarded as a tumor suppressor or an oncogene in different kind of cancer. –,  In our study, DACH1 was found to suppress esophageal cancer growth both in vitro and in vivo. The TGF-β superfamily is a set of multifunctional cytokines that regulate cell growth, differentiation, apoptosis, migration and angiogenesis. – In normal epithelial cells, the TGF-β signaling involves in transcriptional activation of the cyclin-dependent kinase inhibitor p21Cip1, and repression of the growth-promoting transcription factor c-Myc. Cooperatively, these gene responses mediate cell cycle arrest at G1 phase. – TGF-β signaling plays a critical but paradox role in different cancers –. In breast cancer, TGF-β signaling suppresses cell growth in the early stage and promote cancer invasion in the late stage.  Previous study in breast cancer showed that DACH1 inhibited TGF-β signaling through binding Smad4.  While in hepatocellular cancer, we found DACH1 activated TGF-β signaling by increasing p-Smad3. It enhanced repression of c-Myc expression and cell proliferation. .
In support of previous report that DACH1 induced p21 protein abundance and antagonized Myc-induced oncogenic phenotype in breast cancer,  we found here that ectopic expression of DACH1 alone in esophageal cancer cells increased p21 and decreased c-Myc protein level (Fig. 5B). Moreover, DACH1 synergized with TGF-β to enhance induction of p21 and repression of c-Myc; correspondingly, knocking down DACH1 suppressed TGF-β signaling in KYSE140 cells. TGF-β signaling can crosstalk with many other pathways. p53 and smads physically interacted and synergically coregulated TGF-β target genes such as p21 and p15.  Recent studies demonstrated that DACH1 associated with p53 and enhanced p53 function to induce apoptosis and inhibit tumor growth. Further study showed that DACH1 shared occupancy of −15% p53-bound genes in ChIP sequencing. ,  As DACH1 activated TGF-β signaling (Fig. 5A) and induced phosphorylation of smad2/3 (Fig. 5B), a possible explanation is the activation and stabilization of smad2/3 protein complex by DACH1 like p53. However, detail mechanism needs to be proved.
In conclusion, DACH1 is frequently methylated in human esophageal cancer and methylation of DACH1 is involved in the early stage of esophageal carcinogenesis. DACH1 expression is regulated by promoter region hypermethylation. DACH1 suppresses esophageal cancer growth by activating TGF-β signaling.
Conceived and designed the experiments: MZG WL QMZ. Performed the experiments: LW WJY YN. Analyzed the data: LW WJY YN MZG JGH MVB. Contributed reagents/materials/analysis tools: KMW HL. Wrote the paper: LW MZG GPM WL QMZ. Participated in interpretation of data and helped to draft the manuscript: KMW HL GPM JGH MVB.
- 1. Chen W, Zheng R, Zhang S, Zhao P, Li G, et al. (2013) The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 32: 106–112.
- 2. Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
- 3. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.
- 4. Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, et al. (2005) Genetic alterations in esophageal cancer. Surgery today 35: 7–18.
- 5. Sato F, Meltzer SJ (2006) CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106: 483–493.
- 6. Talukdar FR, Ghosh SK, Laskar RS, Mondal R (2013) Epigenetic, genetic and environmental interactions in esophageal squamous cell carcinoma from northeast India. PloS one 8: e60996.
- 7. Chen K, Wu K, Gormley M, Ertel A, Wang J, et al. (2013) Acetylation of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Modules in Breast Cancer. Oncotarget 4: 923–935.
- 8. Wu K, Katiyar S, Witkiewicz A, Li A, McCue P, et al. (2009) The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res 69: 3347–3355.
- 9. Chen K, Wu K, Cai S, Zhang W, Zhou J, et al. (2013) Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer research 73: 3262–3274.
- 10. Nan F, Lu Q, Zhou J, Cheng L, Popov VM, et al. (2009) Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biol Ther 8: 1534–1539.
- 11. Deng XC, Li SR, Zhang Q, Zhou CJ, Yang QF, et al. (2012) [Analysis of the status of DACH1 gene promoter methylation in endometrial carcinoma and its clinical significance]. Zhonghua fu chan ke za zhi 47: 263–267.
- 12. Yan W, Wu K, Herman JG, Brock MV, Fuks F, et al.. (2013) Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics 8.
- 13. Zhu H, Wu K, Yan W, Hu L, Yuan J, et al. (2013) Epigenetic silencing of DACH1 induces loss of transforming growth factor-beta1 antiproliferative response in human hepatocellular carcinoma. Hepatology 58: 2012–2022.
- 14. Guo M, Liu S, Herman JG, Zhuang H, Lu F (2006) Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol Ther 5: 152–155.
- 15. Jia Y, Yang Y, Brock MV, Cao B, Zhan Q, et al. (2012) Methylation of TFPI-2 is an early event of esophageal carcinogenesis. Epigenomics 4: 135–146.
- 16. Jia Y, Yang Y, Zhan Q, Brock MV, Zheng X, et al. (2012) Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer. J Mol Diagn 14: 577–585.
- 17. Guo M, House MG, Suzuki H, Ye Y, Brock MV, et al. (2007) Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer 121: 1219–1226.
- 18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America 93: 9821–9826.
- 19. Jia Y, Yang Y, Liu S, Herman JG, Lu F, et al. (2010) SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics : official journal of the DNA Methylation Society 5: 743–749.
- 20. Wu K, Yang Y, Wang C, Davoli MA, D’Amico M, et al. (2003) DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem 278: 51673–51684.
- 21. Liang F, Lu Q, Sun S, Zhou J, Popov VM, et al. (2012) Increased expression of dachshund homolog 1 in ovarian cancer as a predictor for poor outcome. Int J Gynecol Cancer 22: 386–393.
- 22. Guo M, Ren J, House MG, Qi Y, Brock MV, et al. (2006) Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res 12: 4515–4522.
- 23. Guo M, Ren J, Brock MV, Herman JG, Carraway HE (2008) Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics 3: 336–341.
- 24. Massague J (2008) TGFbeta in Cancer. Cell 134: 215–230.
- 25. Ikushima H, Miyazono K (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415–424.
- 26. Heldin CH, Landstrom M, Moustakas A (2009) Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 21: 166–176.
- 27. Bertolino P, Deckers M, Lebrin F, ten Dijke P (2005) Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 128: 585S–590S.
- 28. Pardali K, Kowanetz M, Heldin CH, Moustakas A (2005) Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1). J Cell Physiol 204: 260–272.
- 29. Chen CR, Kang Y, Siegel PM, Massague J (2002) E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110: 19–32.
- 30. Seoane J (2006) Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 27: 2148–2156.
- 31. Meulmeester E, Ten Dijke P (2011) The dynamic roles of TGF-beta in cancer. J Pathol 223: 205–218.
- 32. Inman GJ (2011) Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 21: 93–99.
- 33. Tian M, Schiemann WP (2009) The TGF-beta paradox in human cancer: an update. Future Oncol 5: 259–271.
- 34. Zu X, Zhang Q, Cao R, Liu J, Zhong J, et al. (2012) Transforming growth factor-beta signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell Tissue Res 347: 73–84.
- 35. Wu K, Li A, Rao M, Liu M, Dailey V, et al. (2006) DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol 26: 7116–7129.
- 36. Elston R, Inman GJ (2012) Crosstalk between p53 and TGF-beta Signalling. J Signal Transduct 2012: 294097.